

## Case-Based Management in AAV: Additional Resources

### **Comparison of the 2022 ACR/EULAR classification criteria for antineutrophil cytoplasmic antibody-associated vasculitis with previous criteria**

Citation: Pyo JY, Lee LE, Park YB, Lee SW. Comparison of the 2022 ACR/EULAR classification criteria for antineutrophil cytoplasmic antibody-associated vasculitis with previous criteria. *Yonsei Med J.* 2023;64(1):11-17. doi:10.3349/ymj.2022.0435

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826961/>

### **2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis**

Citation: Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. *Arthritis Rheumatol.* 2022;74(3):400-406. doi:10.1002/art.41983

Link: <https://www.rheumatology.org/Portals/0/Files/Microscopic-Polyangiitis-Complete-Article.pdf>

### **2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis**

Citation: Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. *Arthritis Rheumatol.* 2022;74(3):393-399. doi:10.1002/art.41986

Link: <https://www.rheumatology.org/Portals/0/Files/Granulomatosis-with-Polyangiitis-Complete-Article.pdf>

### **2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis**

Citation: Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *Arthritis Rheumatol.* 2021;73(8):1366-1383. doi:10.1002/art.41773

Link: <https://onlinelibrary.wiley.com/doi/10.1002/art.41773>

### **EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis**

Citation: Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Ann Rheum Dis*. 2016;75(9):1583-1594. doi:10.1136/annrheumdis-2016-209133

Link: <https://ard.bmj.com/content/75/9/1583>

### **Guidelines: KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases**

Citation: Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int*. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021

Link: <https://pubmed.ncbi.nlm.nih.gov/34556256/>

### **Avacopan for the treatment of ANCA-associated vasculitis**

Citation: Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. *N Engl J Med*. 2021;384(7):599-609. doi:10.1056/NEJMoa2023386

Link: <https://www.nejm.org/doi/full/10.1056/NEJMoa2023386>

### **Rituximab versus cyclophosphamide for ANCA-associated vasculitis**

Citation: Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med*. 2010;363(3):221-232. doi:10.1056/NEJMoa0909905

Link: <https://www.nejm.org/doi/full/10.1056/nejmoa0909905>

### **Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis**

Citation: Walsh M, Merkel PA, Peh CA, et al; PEXIVAS Investigators. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. *N Engl J Med*. 2020;382(7):622-631. doi:10.1056/NEJMoa1803537

Link: <https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803537?articleTools=true>